In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Best of the Blog: IN VIVO, November 2008

Executive Summary

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In November, Windhover's editorial staff posted 28 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included advice from our mothers on how to defrost a Thanksgiving turkey as well as our coverage of the US Presidential election and how it might impact our industry.

You may also be interested in...



The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months

FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March

Turning Back the Clock: Drug Approvals Hit 25 Year Low

You have to go back to 1983 to find a year as bad as 2007 for R&D output. It was a terrible year by any measure. The key question for industry: does it need to learn to subsist on a trickle of new drugs coming to market each year, or is the current drought in fact a sign of a transition to a new, more innovative R&D model? The sparse class of 2007 does offer some glimmers of hope.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel